In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors
for lung cancer include tobacco use, family history, radiation exposure, and the presence of …

Lung cancer has traditionally been classified by histology. However, a greater
understanding of disease biology and the identification of oncogenic driver alterations has …

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …

Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a
strong evidence base for use in patients with cancer. The European Society for Medical …

Introduction Dabrafenib plus trametinib was found to have robust antitumor activity in
patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC). We report updated …

PURPOSE Lorlatinib significantly improved progression-free survival (PFS) versus crizotinib
and showed robust intracranial activity in patients with previously untreated advanced ALK …

Brain metastases occur commonly in patients with advanced solid malignancies. Yet, less is
known about brain metastases than cancer-related entities of similar incidence. Advances in …

Non-small-cell lung cancer (NSCLC) is one of the most common malignancies and the
leading causes of cancer-related death worldwide. Despite many therapeutic advances in …

Compared with traditional therapies, targeted therapy has merits in selectivity, efficacy, and
tolerability. Small molecule inhibitors are one of the primary targeted therapies for cancer …

Lorlatinib is currently the most advanced, potent and selective anaplastic lymphoma kinase
(ALK) tyrosine kinase inhibitor for the treatment of ALK-positive non-small cell lung cancer in …